| Mrs Mary Greco, MS, CCC-SLP/L | |
|
703 Surrey Ln, Algonquin, IL 60102-2014 | |
| (847) 840-9432 | |
| Not Available |
| Full Name | Mrs Mary Greco |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 703 Surrey Ln, Algonquin, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285065037 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 146.001230 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Mary Greco, MS, CCC-SLP/L 703 Surrey Ln, Algonquin, IL 60102-2014 Ph: (847) 840-9432 | Mrs Mary Greco, MS, CCC-SLP/L 703 Surrey Ln, Algonquin, IL 60102-2014 Ph: (847) 840-9432 |
News Archive
University of Houston College of Optometry (UHCO) alumnus Dr. Doug Barnes and his wife, Molly, have made a $5 million pledge to the University of Houston. The gift will be submitted for state matching funds through the Texas Research Incentive Program.
Endothelial progenitor cells may play a role in the start and progression of metastatic disease in children with cancer, according to study results published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Boehringer Ingelheim and Eli Lilly and Company received Marketing Authorisation from the European Commission for Jentadueto which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet.
Psychostimulant use to treat children and adolescents with attention-deficit/hyperactivity disorder (ADHD) is increasing worldwide, and the evaluation of the cardiovascular safety of stimulant medication used in treatment has been a recent topic of concern.
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.
› Verified 8 days ago
Christina Ostien, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2001 W Algonquin Rd, Algonquin, IL 60102 Phone: 708-228-4529 | |
Emilie Naidoff, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1554 E Algonquin Rd, Algonquin, IL 60102 Phone: 847-707-6744 | |
Melissa Sue Aeschliman, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8 White Chapel Ct., Algonquin, IL 60102 Phone: 847-431-6233 | |
Shalynn Morgan, M.ED CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2316 Barrett Dr, Algonquin, IL 60102 Phone: 847-532-1899 | |
Ms. Lisa Kosi, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2324 Loop Rd, Algonquin, IL 60102 Phone: 847-323-1761 Fax: 847-841-3712 | |
Sloth Pediatric Therapy, P.c. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 911 Hayrack Dr., Algonquin, IL 60102 Phone: 847-458-4918 Fax: 847-458-2042 |